John C. Martin Sells 73,333 Shares of Gilead Sciences, Inc. (GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.87% on Friday, hitting $65.92. 5,509,676 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $67.70 and its 200 day moving average is $71.79. Gilead Sciences, Inc. has a 12 month low of $65.38 and a 12 month high of $103.10. The firm has a market cap of $86.16 billion, a P/E ratio of 6.63 and a beta of 1.11.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.61 by $0.09. The company earned $7.30 billion during the quarter, compared to analyst estimates of $7.16 billion. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. Gilead Sciences’s quarterly revenue was down 13.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.32 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.25 earnings per share for the current year.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 30th. Shareholders of record on Thursday, March 16th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 3.13%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.47. The ex-dividend date was Tuesday, March 14th. Gilead Sciences’s payout ratio is presently 18.91%.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/04/21/john-c-martin-sells-73333-shares-of-gilead-sciences-inc-gild-stock-updated.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Hall Laurie J Trustee boosted its stake in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 774 shares during the period. Gemmer Asset Management LLC raised its position in shares of Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the period. Cable Hill Partners LLC raised its position in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the period. Finally, Lombard Odier Transatlantic Limited Partnership raised its position in shares of Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 500 shares during the period. 74.19% of the stock is owned by institutional investors.

Several brokerages have commented on GILD. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $84.73 target price for the company. in a research report on Wednesday, January 4th. Cowen and Company reiterated a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research report on Friday, January 6th. Stifel Nicolaus reiterated a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research report on Wednesday, January 11th. Jefferies Group LLC reiterated a “buy” rating and set a $91.00 target price on shares of Gilead Sciences in a research report on Wednesday, January 4th. Finally, Citigroup Inc lowered shares of Gilead Sciences from a “buy” rating to a “neutral” rating and decreased their price target for the company from $87.00 to $76.00 in a report on Wednesday, February 8th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $83.86.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply